Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Recruiting
Incyte Corporation
Phase 1/Phase 2
2015-02-27
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological
activity of pemigatinib in subjects with advanced malignancies. This study will have three
parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Active, not recruiting
Incyte Corporation
Phase 2
2017-01-12
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a
monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma
harboring FGF/FGFR alterations.
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Completed
Incyte Corporation
Phase 2
2017-01-16
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with
advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation
who have failed at least 1 previous treatment.
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Recruiting
Incyte Corporation
Phase 2
2017-04-25
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828)
in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1
rearrangement.
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
Recruiting
Foundation Medicine, Inc.
Phase 2
2018-07-10
This study will compare the efficacy and safety of molecularly-guided therapy versus standard
platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown
primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of
first-line platinum based induction chemotherapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
